EN
Sinovac Presents at Two Investor Conferences in May 2011
|
Sinovac Presents at Two Investor Conferences in May 2011
Source: Sinovac Biotech Ltd. On Monday May 9, 2011, 8:00 am EDT
BEIJING, May 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ:SVA - News), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are scheduled to present at two upcoming investor conferences in New York City.
•Piper Jaffray 8th Annual China Growth Conference
•Sinovac is scheduled to present at 4:00 pm on Tuesday, May 17, 2011 and will be participating in one-on-one meetings
A live webcast of the presentation will be available online on the Investor Relations Home page of the Sinovac's corporate Web site at http://www.sinovac.com .
•Oppenheimer 5th Annual China Dragon Conference
•Sinovac is scheduled to present at 8:30 am ET on Wednesday, May 18, 2011 and will be participating in one-on-one meetings on May 18 |
|
|
About Sinovac |
|
|
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011. |
|
| Safe Harbor Statement | |
| This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law. | |
|
Helen Yang/Chris Lee Sinovac Biotech Ltd.
|
|
| Tel: | +86-10-8279-9871/9659 |
| Fax: | +86-10-6296-6910 |
| Email: | ir@sinovac.com |
|
Investors: Stephanie Carrington/Amy Glynn
The Ruth Group
|
|
| Tel: | +1-646-536-7017/7023 |
| Email: | |
|
Media: Jason Rando
The Ruth Group
|
|
| Tel: | +1-646-536-7025 |
| Email: | |
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com